Company
Yumanity Therapeutics, Inc.
Headquarters: Boston, MA, United States
Employees: 44
CEO: Dr. Richard Peters M.D., Ph.D.
Market Cap
$20.5 Million
USD as of Dec. 1, 2022
Yumanity Therapeutics, Inc. Categories
United States Healthcare BiotechnologyUnited States Healthcare United States Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $461.52 B |
| Vertex Pharmaceuticals Incorporated | $107.23 B |
| Regeneron Pharmaceuticals, Inc. | $100.01 B |
| CSL Limited | $94.74 B |
| Marinomed Biotech AG | $73.23 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. It focuses on discovering disease-modifying therapies to treat Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer's diseases. Its lead program is YTX-7739, a novel small molecule for the treatment of Parkinson's disease and related disorders of a-synuclein that is in Phase I clinical trial. The company is also developing YTX-9184 for the treatment of dementia with Lewy bodies. Yumanity Therapeutics Inc. has a strategic research and development collaboration agreement with Merck Sharp & Dohme Corp. The company is headquartered in Boston, Massachusetts.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Yumanity Therapeutics, Inc. has the following listings and related stock indices.
Stock: NASDAQ: YMTX wb_incandescent